✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
Clinicians should read both the original Phase IIIb RCT and this correspondence carefully before adopting intratympanic dexamethasone as a routine protocol for preventing cisplatin-induced tinnitus, as the letter may highlight methodological or interpretive concerns.
✦ Why It Matters ✦
Cisplatin-induced ototoxicity (hearing damage from chemotherapy) is a significant and often irreversible side effect in cancer patients; rigorously scrutinizing trial evidence helps ensure sound clinical translation.
✦ Key Points ✦
- 01Published correspondence in Ear and Hearing addresses a Phase IIIb RCT on intratympanic dexamethasone for cisplatin-induced tinnitus.
- 02The original trial by Moreno and Belinchon was a randomized controlled study — a high-quality evidence design.
- 03This letter provides critical or clarifying commentary on that RCT's methodology or conclusions.
- 04Cisplatin ototoxicity (hearing damage from chemotherapy) is the clinical context.
- 05Correspondence does not constitute new primary evidence but may affect interpretation of the original trial.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
Intratympanic dexamethasone may be efficacious in preventing cisplatin-induced tinnitus.
studypartially supported✦ Research metadata ✦
- PMID
- 42545721
- DOI
- 10.1097/AUD.0000000000001879.
- Journal
- Ear and Hearing
- Publication type
- editorial
- Evidence level
- 5
- Population
- Cancer patients receiving cisplatin chemotherapy at risk of tinnitus
- Intervention
- Intratympanic dexamethasone injection for prevention of cisplatin-induced tinnitus
- Comparator
- Placebo or standard care (as per the referenced RCT)
Primary outcomes
Prevention of cisplatin-induced tinnitus